Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

NCT03714373 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

115

Enrollment

INDUSTRY

Sponsor class

Conditions

Prader-Willi Syndrome

Interventions

DRUG: DCCR
DRUG: DCCR
DRUG: Placebo for DCCR

Sponsor

Soleno Therapeutics, Inc.